

**Lantheus Medical Imaging to Host Second Quarter 2012 Conference Call on August 16, 2012 at 4:00 p.m. Eastern Time**

August 10, 2012 3:11 PM ET

**N. Billerica, Mass., August 10, 2012** – Lantheus Medical Imaging, Inc. (“Lantheus”) today announced that it will host a conference call at 4:00 p.m. ET on Thursday, August 16, 2012 to discuss its financial and operating results for the second quarter of 2012.

To access the live conference call via telephone, please dial 1-866-713-8567 (U.S. callers) or 1-617-597-5326 (international callers) and provide passcode 85064915. A live audio webcast of the call also will be available on the homepage of the Company’s website at [www.lantheus.com](http://www.lantheus.com).

A replay of the telephone conference call and audio webcast will be available from approximately 6:00 p.m. ET on August 16, 2012 through midnight on August 30, 2012. To access a replay of the conference call, dial 1-888-286-8010 (U.S. callers) or 1-617-801-6888 (international callers) and provide passcode 58086252.

**About Lantheus Medical Imaging, Inc.**

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company’s proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechnoLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit [www.lantheus.com](http://www.lantheus.com).